Saturday 17 October 2026
Export PTHS’s income statement to Excel — free account
Pelthos Therapeutics Inc.
PTHS Healthcare Biotechnology
In the quarter to June 2026, EPS fell 23.1%, free cash flow fell 1,615.0% and total debt rose 2,692.8%, each against the same quarter a year earlier. Insiders bought in the last twelve months.
20.15
0.11
−0.54%
Follow PTHS
Pelthos Therapeutics Inc. (PTHS) P/E ratio
Pelthos Therapeutics Inc. has no meaningful P/E ratio: its trailing twelve-month earnings is negative. Over the past ten years it has ranged from 0.0× (October 2026) to 0.0× (October 2026) — the current reading is the highest in ten years.
P/E ratio, daily
Embed this chart
Annual newest first
| Period | P/E ratio | Change |
|---|---|---|
| FY2025 | 0.0× | — |
Quarterly newest first
| Period | P/E ratio | Change |
|---|---|---|
| Jun 2026 | 0.0× | — |
| Mar 2026 | 0.0× | — |
| Dec 2025 | 0.0× | — |
| Sep 2025 | 0.0× | — |
Against its own ten years
Low 0.0×
High 0.0×
Ten-year median
0.0×
Current reading's percentile
100
P/E ratio against peers
| Company | P/E ratio |
|---|---|
| ACRV Acrivon Therapeutics, Inc. compare | n/m |
| TELO Telomir Pharmaceuticals, Inc. compare | n/m |
| PTHS Pelthos Therapeutics Inc. | n/m |
| OKYO OKYO Pharma Limited Sponsored ADR compare | n/m |
| CLLS Cellectis S.A. compare | n/m |
| NMRA Neumora Therapeutics, Inc. compare | n/m |
| NTRB Nutriband Inc. compare | n/m |
| CRDF Cardiff Oncology, Inc. compare | n/m |
| PMN Promis Neurosciences compare | n/m |
| Biotechnology industry median | 8.5× |
| Healthcare sector median | 23.0× |
| Market median | 18.1× |
What P/E ratio is
Price to Earnings Ratio shows how much investors pay for each dollar of a company’s annual profit per share.
Stock Price ÷ EPS (Basic) (TTM)